- Home
- GERN vs WERN Comparison
GERN vs WERN Comparison
Compare GERN & WERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GERN | WERN |
|---|---|---|
| Founded | 1990 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 2.3B |
| IPO Year | 1996 | 1994 |
Fundamental Metrics
Financial Performance| Metric | GERN | WERN |
|---|---|---|
| Price | $1.31 | $35.40 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 14 |
| Target Price | $2.17 | ★ $33.79 |
| AVG Volume (30 Days) | ★ 8.8M | 761.8K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.54% |
| EPS Growth | ★ 51.85 | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | $1,065,000.00 | ★ $2,974,396,000.00 |
| Revenue This Year | $26.91 | $22.24 |
| Revenue Next Year | $43.75 | $6.33 |
| P/E Ratio | ★ N/A | $1,167.17 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $23.06 |
| 52 Week High | $2.01 | $47.49 |
Technical Indicators
Market Signals| Indicator | GERN | WERN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 36.92 |
| Support Level | N/A | $32.60 |
| Resistance Level | N/A | $38.82 |
| Average True Range (ATR) | 0.00 | 1.22 |
| MACD | 0.00 | -0.28 |
| Stochastic Oscillator | 0.00 | 19.58 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
About WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company engaged in transporting truckload shipments of general commodities in both interstate and intrastate commerce. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.